Author: Palatin Technologies, Inc.
Published: 29th Dec 2014 - Updated: 12th Jan 2015
Peer-Reviewed Publication: N/A
Additional References: Female Sexual Health Publications
Summary: Palatin Technologies, Inc. has initiated phase 3 reconnect study in the United States for the treatment of female sexual dysfunction.
Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical needs and commercial potential, today announced that it has started its bremelanotide pivotal registration program. The Company has initiated its phase 3 reconnect study in the United States for the treatment of female sexual dysfunction (FSD).
"We are pleased to achieve this major milestone in the bremelanotide program with the initiation of our phase 3 reconnect study in the U.S," stated Carl Spana, Ph.D., President and CEO of Palatin. "This is a key step in our global strategy to bring bremelanotide to market for the millions of women who have FSD and are seeking a safe and effective treatment." Dr. Spana further stated that, "Our recent $30 million financing has provided the financial resources to start the bremelanotide phase 3 pivotal registration program and timing flexibility regarding partnering for the U.S. and other non-European territories."
The start of the reconnect study phase 3 clinical trial in the U.S triggers a development milestone payment of €2.5 million (~$3 million) from Gedeon Richter Plc, Palatin's partner in Europe for bremelanotide for FSD. Palatin is also eligible to receive regulatory and sales milestones, and low double-digit royalties on net sales in the European licensed territory.
Protocol 301 of the reconnect study is a multicenter (~80 sites), randomized, placebo controlled, parallel-group, eight month trial with an open-label extension phase. It is designed to randomize approximately 550 women in North America to evaluate the efficacy and safety of subcutaneous bremelanotide in premenopausal women with hypoactive sexual desire disorder (HSDD) as an on-demand, as-needed treatment. Initial data from the study is anticipated in the middle of calendar year 2016. More information on the trial protocol, including trial design, inclusion/exclusion criteria, etc., can be found at http://clinicaltrials.gov
About Bremelanotide for Female Sexual Dysfunction
Palatin is developing bremelanotide subcutaneous for the treatment of FSD in premenopausal women diagnosed with FSD. Bremelanotide, which is a melanocortin agonist (a compound which binds to a cell receptor and triggers a response) drug candidate, is a synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone).
About Female Sexual Dysfunction
Female Sexual Dysfunction covers multi-factorial conditions that have anatomical, physiological, medical, psychological and social components. We will seek approval of bremelanotide for the largest category of FSD, hypoactive sexual desire disorder. To establish a diagnosis of FSD, one or more of the disorders making up FSD must be associated with personal distress, as determined by the affected women.i A study of more than 30,000 U.S. women in 2008 reported an age-adjusted point prevalence of sexual difficulties causing personal distress in 12 percent of respondents.ii
There are no drugs in the United States approved for the treatment of FSD. Bremelanotide is an on-demand, as-needed treatment and has the potential to transform the treatment of patients with FSD.
|Latest Female Sexual Health Publications|
The above information is from our reference library of resources relating to Female Sexual Health that includes:
|Effect of Sexual Orientation on Sexual Function and Distress|
A new study suggests cisgender heterosexual women are more satisfied in relationships and have fewer depression and anxiety symptoms than cisgender sexual minority women.
Publish Date: 27th Sep 2023
|Gender Stereotypes Impact Diagnosis of Girls with Developmental Language Disorder|
Researchers examine the consequences of sexist myths on development of language, communication, and the social and emotional spheres among children.
Publish Date: 6th Feb 2023
|A Tale of Three Women: Vaginismus, Menopause, and Sexual Anhedonia|
Three women with separate stories of sexual issues and discoveries.
Publish Date: 31st Jan 2023
|Excessive Travel Times to Obtain an Abortion in America|
A third of women of reproductive age in the United States face excessive travel times to obtain an abortion after U.S. Supreme Court Dobbs v. Jackson decision.
Publish Date: 1st Nov 2022
1How Many Genders Are There?
Alphabetical list of gender identities.
2Transgender Reporting Guide
How to write about transgender people.
3Glossary of Sexuality Terms
Definitions of sexual terms & acronyms.
4Glossary of Gender Terms
Definitions of gender related terms.
5Am I Gay? Questions to Ask
Think you may be gay or bisexual?
• Submissions: Send us your coming events and LGBTQ related news stories.
• Report Errors: Please report outdated or inaccurate information to us.
• (APA): Palatin Technologies, Inc.. (2014, December 29). Female Sexual Dysfunction: Bremelanotide Phase 3 Program. SexualDiversity.org. Retrieved December 5, 2023 from www.sexualdiversity.org/sexuality/health/female/280.php
• Permalink: <a href="https://www.sexualdiversity.org/sexuality/health/female/280.php">Female Sexual Dysfunction: Bremelanotide Phase 3 Program</a>